skip to main content
Close Icon

This website uses cookies. By continuing to use this site, you agree to our use of cookies. To find out more visit our Cookie Policy page.

Global Search Configuration

Our specialisms

​Gain a competitive edge with comprehensive clinical trial intelligence. Find out what competitors are doing in key areas, understand regulations and identify sites and investigators.
See the entire global biopharma market landscape in one place: our expert analysis and trusted databases cover all sectors of the industry.
​Drive commercial success with customized dashboards, data visualization, scenario modeling and more.
​Identify M&A targets and partnership opportunities, and develop business cases with our real-time intelligence, tools and analysis.
​An increasingly complex regulatory framework for the pharmaceutical, biotech and medtech industries presents growing challenges to businesses. We’ll help you stay ahead.
​​To succeed in medtech, you need to have your finger on the pulse – but accurate, reliable information is not always easy to find.

Relevant products

pdpimage

Trialtrove

The industry’s gold standard for clinical trials intelligence, made by experts for experts

pdpimage

Datamonitor Healthcare

Datamonitor Healthcare's expert coverage of key diseases, companies, drugs and market trends makes it the go-to product for pharmaceutical and biotechnology companies to support the development and validation of their strategic plans and commercial decisions.

pdp image

Scrip

Timely news and in-depth insight. Essential for anyone making commercial decisions in the pharmaceutical industry.

Pharma Intelligence latest insights

  • Clinical trial intelligence

    Pharmaprojects

    AiCuris seeks partners for antibacterial programs

    07 Dec 2016

    AiCuris CEO Holger Zimmermann talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the company's journey to becoming a clinical biotech company since being spun out of Bayer AG as a small research group a decade ago. Zimmermann highlights AiCuris's anti-infectives development pipeline, the next big goals for the company and how new partners might fit into its plans. AiCuris already has an exclusive worldwide licensing agreement in place with Merck & Co. for its lead compound, letermovir (AIC246), an oral, late-stage antiviral candidate being investigated for the treatment and prevention of human cytomegalovirus (HCMV) infection in transplant recipients. AiCuris received a EUR 110 million upfront payment from Merck as part of this deal, which covers AiCuris's novel portfolio of investigational HCMV medicines.

  • Clinical trial intelligence

    Pharmaprojects

    BioNTechs Sean Marett explains Genentech deal rationale

    07 Dec 2016

    Chief operating officer of BioNTech, Sean Marett, talks to Mike Ward, global director of content for Informa Pharma Intelligence, about the German firm's recent co-development deal with Roche company, Genentech. On the sidelines of the recent BIO-Europe® partnering conference, held in Cologne Germany, Marett outlines the benefits of this collaboration, such as access to the US market and regulatory expertise. This deal will be highlighted as part of a deal case study session at The One Nucleus Genesis meeting in London on December 1, 2016.

  • Clinical trial intelligence

    Pharmaprojects

    Cinfa outlines biosimilar development areas and deal opportunities

    07 Dec 2016

    Cinfa Biotech's managing director, Ruediger Jankowsky, chats with Mike Ward, global director of content for Informa Pharma Intelligence, about the company's founding and focus on biosimilar drug development. They discuss Cinfa's biosimilars business model, disease areas of focus and potential deals for the company in the near future.

  • Clinical trial intelligence

    Pharmaprojects

    Dimerix CEO explains companys different drug combo R and D strategy

    07 Dec 2016

    Global director of content for Informa Pharma Intelligence, Mike Ward, talks to Kathy Harrison, CEO of Australian biotech Dimerix, about the company's unusual business model. They discuss Dimerix's Receptor-Heteromer Investigation Technology (HIT) platform and how it is used by the company and its partners. Dimerix's pipeline is based on combining existing therapies with new drugs, a system it believes helps to lower risk to the company during the R&D phase. Dimerix's lead compound is DMX-200, a Phase II chronic kidney disease treatment. DMX-200 is a combination of two existing drugs, irbesartan and propagermanium, which are already on the market in various regions around the world.

  • Clinical trial intelligence

    Pharmaprojects

    eTheRNA CEO outlines development plan in cancer RNA space

    07 Dec 2016

    Mike Ward, global director of content for Informa Pharma Intelligence, interviews Dirk Reyn, CEO of eTheRNA, on the sidelines of the BIO-Europe® partnering conference in Cologne, Germany. The pair discusses eTheRNA's emerging cancer immunotherapy pipeline, funding prospects and the next steps for the company—which was founded in 2013—as it looks to expand its business.

  • Clinical trial intelligence

    Pharmaprojects

    F star business chief discuss Denali deal and potential F star delta spinout

    07 Dec 2016

    Jane Dancer, chief business officer at F-star—a Cambridge, UK-based biotech—chats with Mike Ward, global director of content for Informa Pharma Intelligence, on the sidelines of the recent BIO-Europe® partnering conference in Cologne, Germany. The pair discusses F-star's asset-centric business strategy, the company's recent deal with Denali Therapeutics and when we might see another spinout business from F-Star. The company’s recent deal is the subject of a deal case study at The One Nucleus Genesis meeting in London on December 1, 2016.

  • Clinical trial intelligence

    Pharmaprojects

    How are regulatory changes affecting early stage R and D in China

    07 Dec 2016

    Darren Ji, former VP and global head of Asia and emerging markets at Roche, chats with Mike Ward, global director of content for Informa Pharma Intelligence, about current trends disrupting the pharma sector in China.  Darren Ji took part in a panel at BIO-Europe® 2016 focused on changes in the Chinese pharma industry. He discusses the recent crackdown on clinical data quality by the China FDA and regulatory changes for early stage R&D in the region.

  • Clinical trial intelligence Competitive and market intelligence

    Trialtrove

    Kinase inhibitors in rheumatoid arthritis: where have they been and where are they going?

    By ​Gunilla Sturrock 07 Dec 2016

    This analysis provides a five year review of the RA kinase inhibitor programs – where have they been and where are they going.

    Topics Clinical trial optimization

  • Clinical trial intelligence Competitive and market intelligence

    Trialtrove

    2016 Clinical trials roundup: Steady Course or changing tides?

    By Doro Shin 07 Dec 2016

    Welcome to this year’s roundup where we’ll review clinical trials that initiated in 2015 to elucidate any ongoing, or new, trends within the world of pharma R&D.

    Topics Clinical trials

  • Clinical trial intelligence Competitive and market intelligence

    Trialtrove

    Collaborations in HIV treatment trials: A help or hindrance for patient recruitment?

    By Doro Shin 07 Dec 2016

    This analysis takes a closer look at Phase II-III studies in HIV positive patients in order to determine what effect collaboration has on enrollment trends in clinical trials evaluating antiretroviral treatment, if any.

    Topics Clinical trial optimization

  • Clinical trial intelligence Competitive and market intelligence

    Trialtrove

    Reporting Bias in Clinical Trials: What’s the current status?

    By Doro Shin 07 Dec 2016

    Citeline is pleased to report that by using Trialtrove to analyze a wide variety of sources, clinical trial transparency is in a much healthier state than shown in previous studies.

    Topics Clinical trials

  • Clinical trial intelligence Competitive and market intelligence

    Trialtrove

    The Effect of Geographic Breadth on Enrollment

    By Doro Shin 07 Dec 2016

    Projecting timelines and identifying sites are key elements to consider while planning clinical trials.

    Topics Clinical trials

  • Medtech competitive intelligence

    Meddevicetracker

    Meddevicetracker Weekly Round-Up

    By Edward Stopke 06 Dec 2016

    Topics Medtech weekly roundup

  • Business development and licensing Competitive and market intelligence

    Scrip

    Novartis, Kite Neck-And-Neck In CAR-T Race; Deaths Keep Juno In Third Place

    By Mandy Jackson 04 Dec 2016

    Novartis and Kite both are set to submit their CD19-targeting CAR-T therapies for US FDA approval in early 2017, while neurotoxic deaths for two of Juno’s product candidates cast doubts on its programs.

  • Clinical trial intelligence Competitive and market intelligence

    Trialtrove

    Innovation In Heart Failure Drug Development - Is There Enough?

    By Jake Mathon 02 Dec 2016

    Heart failure is a chronic condition that is of major concern to the healthcare community. 5.8 million Americans and 23 million people globally are estimated to have heart failure.

    Topics Clinical trial optimization

;

Next steps

Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.

Request live demo now:

Our team is always happy to hear from you. Please call us at:

  • US Toll-Free  : +1 888-670-8900
  • US Toll           : +1 908-547-2200
  • UK & Europe : +44 (20) 337 73737
  • Australia       : +61 2 8705 6907

Or email us your inquiry, so we can provide you the best possible customer service:
Pharma@informa.com

Have an immediate and specific information need?

Browse and buy from 1000s of analysis and research reports now: